Cone- and rod-mediated multifocal electroretinogram in early age-related maculopathy

Cone-mediated multifocal electroretinogram in age-related macular degeneration: progression over a long-term follow-up.

OBJECTIVE To evaluate the progression of change in the cone-driven multifocal electroretinogram (mfERG) responses in patients previously identified as having high-risk, soft drusen 63 mum or greater. METHODS Seventeen eyes of 14 patients were reevaluated after 28 to 41 months. Fundus changes were graded depending on drusen size and extent. Each of the 103 mfERG responses was analyzed and comp...

Impact of aging and age-related maculopathy on inactivation of the a-wave of the rod-mediated electroretinogram

PURPOSE To examine the impact of aging and age-related maculopathy (ARM) on the activation of phototransduction in rod photoreceptors by measuring the a-wave of the flash, full-field electroretinogram (ERG). METHODS Enrollees consisted of older adults (> or = 60 years of age) in normal retinal health (n = 41) and those with early (n = 39) or late ARM (n = 7), in whom disease presence and seve...

Age-related maculopathy: a multifocal approach

Adaptation responses in early age-related maculopathy.

PURPOSE To investigate the global-flash multifocal electroretinogram (mfERG) in early age-related maculopathy (ARM). METHODS Thirty-two eyes from 20 healthy control subjects and 12 age-matched subjects with early ARM were investigated with the conventional and the global-flash mfERG. Early ARM subjects were graded according to an international grading system. The conventional mfERG consisted ...

Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration.

PURPOSE To evaluate changes in the multifocal electroretinogram (mfERG) in patients with neovascular age-related macular degeneration (nAMD) undergoing ranibizumab treatment. METHODS This was an observational, longitudinal, prospective study. Treatment-naive patients with nAMD who met the inclusion and exclusion criteria underwent a course of monthly injections of ranibizumab over 3 months. A...